BIOMAT Database Logo BIOMAT Database Logo

Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. 1995

E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Eijkman-Winkler Institute for Medical and Clinical Microbiology, Utrecht University, Netherlands.

Relationships between in vitro parameters (opsonic activity and anti-pneumococcal polysaccharide [PS] antibody subclasses) and in vivo mouse protection were established by logistic regression analysis. Data were from 158 mice challenged with pneumococci after vaccination with synthetic oligosaccharide- and PS-protein conjugates in combination with the adjuvant Quil A. The hypothesis that serum opsonic activity has predictive value for protection against pneumococcal infection was tested. Serum opsonic activity was well correlated with protection (chi 2 = 35.5, P < 0.001), although a stronger correlation was observed for anti-PS IgM and IgG. The combined use of IgG and opsonic activity as predictor variables yielded the best fitting model for predicting protection (chi 2 = 74.1, P < 0.001). When opsonic activity data were added to models that included various antibody isotypes, the statistical significance of the models was enhanced. Thus, the opsonic activity of antisera induced by pneumococcal vaccines can predict mouse protection.

UI MeSH Term Description Entries
D007132 Immunoglobulin Isotypes The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties. Antibody Class,Ig Isotype,Ig Isotypes,Immunoglobulin Class,Immunoglobulin Isotype,Antibody Classes,Immunoglobulin Classes,Class, Antibody,Class, Immunoglobulin,Classes, Antibody,Classes, Immunoglobulin,Isotype, Ig,Isotype, Immunoglobulin,Isotypes, Ig,Isotypes, Immunoglobulin
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009895 Opsonin Proteins Proteins that bind to particles and cells to increase susceptibility to PHAGOCYTOSIS, especially ANTIBODIES bound to EPITOPES that attach to FC RECEPTORS. COMPLEMENT C3B may also participate. Opsonin,Opsonin Protein,Opsonins,Protein, Opsonin
D011008 Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE. Streptococcus pneumoniae Infections,Infections, Pneumococcal,Infections, Streptococcus pneumoniae,Pneumococcal Diseases,Disease, Pneumococcal,Diseases, Pneumococcal,Infection, Pneumococcal,Infection, Streptococcus pneumoniae,Pneumococcal Disease,Pneumococcal Infection,Streptococcus pneumoniae Infection
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D005260 Female Females
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial

Related Publications

E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.
September 1978, The Journal of experimental medicine,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody.
April 1982, Infection and immunity,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.
April 2007, Infection and immunity,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice.
April 2009, Infection and immunity,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Low opsonic activity in sera from HIV-infected patients against Streptococcus pneumoniae.
November 1993, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Opsonic activity of "anti-Ia"-like enhancing antisera.
June 1977, Transplantation,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Sortase A confers protection against Streptococcus pneumoniae in mice.
July 2009, Infection and immunity,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Protective effect of Plantago major L. Pectin polysaccharide against systemic Streptococcus pneumoniae infection in mice.
October 2000, Scandinavian journal of immunology,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
4-1BB (CD137) differentially regulates murine in vivo protein- and polysaccharide-specific immunoglobulin isotype responses to Streptococcus pneumoniae.
January 2003, Infection and immunity,
E Alonso De Velasco, and B A Dekker, and A F Verheul, and R G Feldman, and J Verhoef, and H Snippe
Serum opsonic deficiency produced by Streptococcus pneumoniae and by capsular polysaccharide antigens.
January 1978, The Yale journal of biology and medicine,
Copied contents to your clipboard!